Boston Scientific Corporation $BSX Shares Sold by National Pension Service

National Pension Service decreased its position in Boston Scientific Corporation (NYSE:BSX) by 4.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,375,933 shares of the medical equipment provider’s stock after selling 147,209 shares during the period. National Pension Service’s holdings in Boston Scientific were worth $362,609,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Brighton Jones LLC raised its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. CWM LLC raised its holdings in Boston Scientific by 8.2% in the 1st quarter. CWM LLC now owns 37,476 shares of the medical equipment provider’s stock valued at $3,781,000 after acquiring an additional 2,844 shares during the last quarter. Signaturefd LLC lifted its position in Boston Scientific by 10.9% during the first quarter. Signaturefd LLC now owns 32,421 shares of the medical equipment provider’s stock worth $3,271,000 after buying an additional 3,184 shares in the last quarter. Apollon Wealth Management LLC raised its holdings in shares of Boston Scientific by 12.5% during the 1st quarter. Apollon Wealth Management LLC now owns 22,897 shares of the medical equipment provider’s stock worth $2,310,000 after acquiring an additional 2,542 shares during the period. Finally, SBI Securities Co. Ltd. raised its stake in Boston Scientific by 27.6% during the first quarter. SBI Securities Co. Ltd. now owns 3,063 shares of the medical equipment provider’s stock worth $309,000 after purchasing an additional 662 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 1.6%

BSX opened at $102.53 on Wednesday. The business has a fifty day moving average price of $99.92 and a 200 day moving average price of $102.53. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The stock has a market capitalization of $151.99 billion, a price-to-earnings ratio of 54.83, a PEG ratio of 2.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period last year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. The trade was a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 175,782 shares of company stock worth $17,742,314 over the last three months. 0.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on BSX shares. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price target for the company from $118.00 to $125.00 in a research note on Monday, September 8th. The Goldman Sachs Group reissued a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, October 22nd. Morgan Stanley boosted their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Finally, Barclays upped their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.